Astellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month High – Should You Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $12.72 and last traded at $12.14, with a volume of 92947 shares changing hands. The stock had previously closed at $12.26.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Sanford C. Bernstein downgraded Astellas Pharma from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 2nd. Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Astellas Pharma Stock Performance

The company has a quick ratio of 0.89, a current ratio of 1.17 and a debt-to-equity ratio of 0.38. The stock’s 50 day moving average price is $11.10 and its two-hundred day moving average price is $10.47.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Thursday, October 30th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.20 by $0.10. The company had revenue of $3.45 billion during the quarter, compared to the consensus estimate of $3.14 billion. Astellas Pharma had a net margin of 6.39% and a return on equity of 22.73%. On average, sell-side analysts predict that Astellas Pharma Inc. will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.